Introduction
============

Severe sepsis and septic shock remain the most serious problem of critical care medicine with a mortality rate of 30 to 55% \[[@B1]\]. Several studies have demonstrated positive effects of selective adsorption of LPS on blood pressure, PaO~2~/FiO~2~ratio, endotoxin removal and mortality \[[@B2],[@B3]\]. The purpose of the study was to evaluate the efficiency of using the selective adsorption of LPS, Toraymyxin - PMX-F (Toray, Japan) and Alteco^®^LPS Adsorber (Alteco Medical AB, Sweden), in the complex treatment of patients with severe sepsis.

Methods
=======

Forty-six patients with Gram-negative sepsis in the postoperative period were enrolled into the study. Toraymyxin - PMX-F was used in the PMX-F group (*n*= 14), while Alteco LPS adsorption was used in the Alteco LPS group (*n*= 32). The clinical characteristics are listed in Table [1](#T1){ref-type="table"}. The SOFA score, PaO~2~/FiO~2~, procalcitonin (PCT), C-reactive protein (CRP), endotoxin activity assay (EAA) was noted before, 24 and 48 hours after the selective adsorption of LPS.

###### 

Clinical characteristics of the groups

  Characteristic   PMX-F         Alteco LPS
  ---------------- ------------- -------------
  Sex M/F          9/5           17/15
  Age (years)      41.6 ± 17.1   42.1 ± 13.5
  Shock            6 (42.9%)     13 (40.6%)
  APACHE II        21 (17; 25)   21 (16; 24)
  SOFA             7 (3.0; 8)    7 (3.5; 11)

Results
=======

At 48 hours after PMX-F, significantly decreased PCT from 17.5 (5.0; 40.9) to 7.1 (4.8; 13.0) ng/ml, *P*= 0.028, decreased CRP from 180 (133; 286) to 132 (68; 155) mg/l, *P*= 0.015 and SOFA score from 7.0 (3,0; 8.0) to 6.0 (3,0; 7.0), *P*= 0.007. At 24 hours after Alteco LPS, significantly decreased PCT from 8.7 (3.0; 25.9) to 4.8 (2.1; 10.0) ng/ml. The 28-day mortality rate was 14.2% (*n*= 2) in the PMX-F group and 31.3% (*n*= 10) in the Alteco LPS group.

Conclusion
==========

The use of the LPS-selective adsorption (particularly PMX-F) in patients with severe sepsis leads to improvement of systemic inflammation and organ dysfunction.
